Cholesterol removal as a treatment for dry age-related macular degeneration

Ended Project Grant Awarded Last action

Award ID
R43EY035876
Recipient
Awarding agency
Obligated
$276,758

Award facts

Assistance listing
93.867 Vision Research
Completion date
Place of performance
Washington, DC, USA

Award details come from USAspending.gov.

Description

Abstract
The leading cause of blindness in people over 50 in industrialized nations including the united states is age-related macular degeneration (AMD). Early AMD is characterized by cholesterol accumulation under the neurosensory retina called sub-retinal drusenoid deposits or under the retinal pigment epithelium called drusen. Vision loss occurs in advanced AMD, with "wet" AMD comprising 20% of cases driven by angiogenesis, or from "dry" AMD (80% of cases) driven by cholesterol accumulation and accompanying cell death (geographic atrophy). Mobius has an expert team in cholesterol biology, lipid transport in the eye, lipoprotein nanoparticle (nanodisc) production, and human therapeutics to tackle cholesterol removal from the eye. The phase 1 goal is to demonstrate the feasibility of optimized nanodisc technology to facilitate cholesterol removal, and demonstrate therapeutic potential to treat cholesterol accumulation to treat dry AMD. The aims of phase 1 will be to initially design the optimal prototype nanodisc for cholesterol removal, and then test that prototype in cells and pre-clinical models of relevance in AMD.

Transactions

Action Obligated Date
Amendment $0
Original award $276,758

Quick answers

Who received award R43EY035876?

R43EY035876 was awarded to Mobius Scientific Inc. by National Eye Institute (National Institutes of Health) on April 1, 2024.

How much is award R43EY035876 worth?

$276,758 has been obligated on R43EY035876.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award